MedPath

Onvansertib

Generic Name
Onvansertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H27F3N8O3
CAS Number
1034616-18-6
Unique Ingredient Identifier
67RM91WDHQ
Background

Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

Associated Conditions
-
Associated Therapies
-

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2
Completed
Conditions
Metastatic Colorectal Cancer
Colorectal Cancer
Interventions
First Posted Date
2022-10-25
Last Posted Date
2025-01-10
Lead Sponsor
Cardiff Oncology
Target Recruit Count
23
Registration Number
NCT05593328
Locations
๐Ÿ‡บ๐Ÿ‡ธ

San Juan Oncology Associates, Farmington, New Mexico, United States

๐Ÿ‡บ๐Ÿ‡ธ

Pacific Cancer Medical Center, Anaheim, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Washington University School of Medicine Center for Advanced Medicine, Saint Louis, Missouri, United States

and more 24 locations

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Phase 1
Recruiting
Conditions
Recurrent Chronic Myelomonocytic Leukemia
Refractory Chronic Myelomonocytic Leukemia
Recurrent Atypical Chronic Myeloid Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Recurrent Myelodysplastic/Myeloproliferative Neoplasm
Refractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Onvansertib
Procedure: Ultrasound Imaging
First Posted Date
2022-09-22
Last Posted Date
2025-01-06
Lead Sponsor
Mayo Clinic
Target Recruit Count
25
Registration Number
NCT05549661
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2
Completed
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2021-02-12
Last Posted Date
2025-01-07
Lead Sponsor
Cardiff Oncology
Target Recruit Count
43
Registration Number
NCT04752696
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic Jacksonville, Jacksonville, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Inova Schar Cancer Institute, Fairfax, Virginia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 3 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath